Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Nissim Benvenisty is active.

Publication


Featured researches published by Nissim Benvenisty.


Nature Biotechnology | 2007

Characterization of human embryonic stem cell lines by the International Stem Cell Initiative

Oluseun Adewumi; Behrouz Aflatoonian; Lars Ährlund-Richter; Michal Amit; Peter W. Andrews; Gemma Beighton; Paul Bello; Nissim Benvenisty; Lorraine S. Berry; Simon Bevan; Barak Blum; Justin Brooking; Kevin G. Chen; Andre Choo; Gary A. Churchill; Marie Corbel; Ivan Damjanov; John S Draper; Petr Dvorak; Katarina Emanuelsson; Roland A. Fleck; Angela Ford; Karin Gertow; Marina Gertsenstein; Paul J. Gokhale; Rebecca S. Hamilton; Alex Hampl; Lyn Healy; Outi Hovatta; Johan Hyllner

The International Stem Cell Initiative characterized 59 human embryonic stem cell lines from 17 laboratories worldwide. Despite diverse genotypes and different techniques used for derivation and maintenance, all lines exhibited similar expression patterns for several markers of human embryonic stem cells. They expressed the glycolipid antigens SSEA3 and SSEA4, the keratan sulfate antigens TRA-1-60, TRA-1-81, GCTM2 and GCT343, and the protein antigens CD9, Thy1 (also known as CD90), tissue-nonspecific alkaline phosphatase and class 1 HLA, as well as the strongly developmentally regulated genes NANOG, POU5F1 (formerly known as OCT4), TDGF1, DNMT3B, GABRB3 and GDF3. Nevertheless, the lines were not identical: differences in expression of several lineage markers were evident, and several imprinted genes showed generally similar allele-specific expression patterns, but some gene-dependent variation was observed. Also, some female lines expressed readily detectable levels of XIST whereas others did not. No significant contamination of the lines with mycoplasma, bacteria or cytopathic viruses was detected.


Cell Stem Cell | 2009

Induced Pluripotent Stem Cells and Embryonic Stem Cells Are Distinguished by Gene Expression Signatures

Mark H. Chin; Mike J. Mason; Wei Xie; Stefano Volinia; Mike Singer; Cory Peterson; G. Ambartsumyan; Otaren Aimiuwu; Laura Richter; Jin Zhang; Ivan Khvorostov; Vanessa Ott; Michael Grunstein; Neta Lavon; Nissim Benvenisty; Carlo M. Croce; Amander T. Clark; Tim Baxter; April D. Pyle; Michael A. Teitell; Matteo Pelegrini; Kathrin Plath; William E. Lowry

Induced pluripotent stem cells (iPSCs) outwardly appear to be indistinguishable from embryonic stem cells (ESCs). A study of gene expression profiles of mouse and human ESCs and iPSCs suggests that, while iPSCs are quite similar to their embryonic counterparts, a recurrent gene expression signature appears in iPSCs regardless of their origin or the method by which they were generated. Upon extended culture, hiPSCs adopt a gene expression profile more similar to hESCs; however, they still retain a gene expression signature unique from hESCs that extends to miRNA expression. Genome-wide data suggested that the iPSC signature gene expression differences are due to differential promoter binding by the reprogramming factors. High-resolution array profiling demonstrated that there is no common specific subkaryotypic alteration that is required for reprogramming and that reprogramming does not lead to genomic instability. Together, these data suggest that iPSCs should be considered a unique subtype of pluripotent cell.


Proceedings of the National Academy of Sciences of the United States of America | 2002

Characterization of the expression of MHC proteins in human embryonic stem cells

Micha Drukker; Gil Katz; Achia Urbach; Maya Schuldiner; Gal Markel; Joseph Itskovitz-Eldor; Benjamin E. Reubinoff; Ofer Mandelboim; Nissim Benvenisty

Human embryonic stem (ES) cells are pluripotent cells that may be used in transplantation medicine. These cells can be induced to differentiate into cells from the three embryonic germ layers both in vivo and in vitro. To determine whether human ES cells might be rejected after transplantation, we examined cell surface expression of the MHC proteins in these cells. Our results show very low expression levels of MHC class I (MHC-I) proteins on the surface of human ES cells that moderately increase on in vitro or in vivo differentiation. A dramatic induction of MHC-I proteins was observed when the cells were treated with IFN-γ but not with IFN-α or -β. However, all three IFNs induced expression of MHC-I proteins in differentiated human ES cells. MHC-II proteins and HLA-G were not expressed on the surface of undifferentiated or differentiated cells. Ligands for natural killer cell receptors were either absent or expressed in very low levels in human ES cells and in their differentiated derivatives. In accordance, natural killer cytotoxic assays demonstrated only limited lysis of both undifferentiated and differentiated cells. To initiate a histocompatibility databank of human ES cells, we have isotyped several of the published ES cell lines for their human leukocyte antigens. In conclusion, our results demonstrate that human ES cells can express high levels of MHC-I proteins and thus may be rejected on transplantation.


Cell Stem Cell | 2010

Identification and Classification of Chromosomal Aberrations in Human Induced Pluripotent Stem Cells

Yoav Mayshar; Uri Ben-David; Neta Lavon; Juan-Carlos Biancotti; Benjamin Yakir; Amander T. Clark; Kathrin Plath; William E. Lowry; Nissim Benvenisty

Because of their somatic cell origin, human induced pluripotent stem cells (HiPSCs) are assumed to carry a normal diploid genome, and adaptive chromosomal aberrations have not been fully evaluated. Here, we analyzed the chromosomal integrity of 66 HiPSC and 38 human embryonic stem cell (HESC) samples from 18 different studies by global gene expression meta-analysis. We report identification of a substantial number of cell lines carrying full and partial chromosomal aberrations, half of which were validated at the DNA level. Several aberrations resulted from culture adaptation, and others are suspected to originate from the parent somatic cell. Our classification revealed a third type of aneuploidy already evident in early passage HiPSCs, suggesting considerable selective pressure during the reprogramming process. The analysis indicated high incidence of chromosome 12 duplications, resulting in significant enrichment for cell cycle-related genes. Such aneuploidy may limit the differentiation capacity and increase the tumorigenicity of HiPSCs.


Nature Reviews Cancer | 2011

The tumorigenicity of human embryonic and induced pluripotent stem cells.

Uri Ben-David; Nissim Benvenisty

The unique abilities of human pluripotent stem cells to self-renew and to differentiate into cells of the three germ layers make them an invaluable tool for the future of regenerative medicine. However, the same properties also make them tumorigenic, and therefore hinder their clinical application. Hence, the tumorigenicity of human embryonic stem cells (HESCs) has been extensively studied. Until recently, it was assumed that human induced pluripotent stem cells (HiPSCs) would behave like their embryonic counterparts in respect to their tumorigenicity. However, a rapidly accumulating body of evidence suggests that there are important genetic and epigenetic differences between these two cell types, which seem to influence their tumorigenicity.


Brain Research | 2001

Induced neuronal differentiation of human embryonic stem cells

Maya Schuldiner; Rachel Eiges; Amir Eden; Ofra Yanuka; Joseph Itskovitz-Eldor; Ronald S. Goldstein; Nissim Benvenisty

Human embryonic stem (ES) cells are pluripotent cells capable of forming differentiated embryoid bodies (EBs) in culture. We examined the ability of growth factors under controlled conditions to increase the number of human ES cell-derived neurons. Retinoic acid (RA) and nerve growth factor (betaNGF) were found to be potent enhancers of neuronal differentiation, eliciting extensive outgrowth of processes and the expression of neuron-specific molecules. Our findings show that human ES cells have great potential to become an unlimited cell source for neurons in culture. These cells may then be used in transplantation therapies for neural pathologies.


Stem Cells | 2006

Human Embryonic Stem Cells and Their Differentiated Derivatives Are Less Susceptible to Immune Rejection Than Adult Cells

Micha Drukker; Helena Katchman; Gil Katz; Smadar Friedman; Elias Shezen; Eran Hornstein; Ofer Mandelboim; Yair Reisner; Nissim Benvenisty

Differentiated cell types derived from human embryonic stem cells (hESCs) may serve in the future to treat various human diseases. A crucial step toward their successful clinical application is to examine the immune response that might be launched against them after transplantation. We used two experimental platforms to examine the in vivo leukocyte response toward hESCs. First, immunocompetent and immunodeficient mouse strains were used to identify T cells as the major component that causes xenorejection of hESCs. Second, mice that were conditioned to carry peripheral blood leukocytes from human origin were used to test the human leukocyte alloresponse toward undifferentiated and differentiated hESCs. Using this model, we have detected only a minute immune response toward undifferentiated as well as differentiated hESCs over the course of 1 month, although control adult grafts were repeatedly infiltrated with lymphocytes and destroyed. Our data show that the cells evade immune destruction due to a low immunostimulatory potential. Nevertheless, a human cytotoxic T lymphocyte clone that was specifically prepared to recognize two hESC lines could lyse the cells after major histocompatibility complex class I (MHC‐I) induction. Although MHC‐I levels in hESCs are sufficient for rejection by cytotoxic T cells, our data suggest that the immunostimulatory capacity of the cells is very low. Thus, immunosuppressive regimens for hESC‐based therapeutics could be highly reduced compared with conventional organ transplantation because direct allorejection processes of hESCs and their derivatives are considerably weaker.


Current Biology | 2001

Establishment of human embryonic stem cell-transfected clones carrying a marker for undifferentiated cells

Rachel Eiges; Maya Schuldiner; Micha Drukker; Ofra Yanuka; Joseph Itskovitz-Eldor; Nissim Benvenisty

Human embryonic stem (ES) cells are pluripotent cell lines that have been derived from the inner cell mass (ICM) of blastocyst stage embryos [1--3]. They are characterized by their ability to be propagated indefinitely in culture as undifferentiated cells with a normal karyotype and can be induced to differentiate in vitro into various cell types [1, 2, 4-- 6]. Thus, human ES cells promise to serve as an unlimited cell source for transplantation. However, these unique cell lines tend to spontaneously differentiate in culture and therefore are difficult to maintain. Furthermore, colonies may contain several cell types and may be composed of cells other than pluripotent cells [1, 2, 6]. In order to overcome these difficulties and establish lines of cells with an undifferentiated phenotype, we have introduced a reporter gene that is regulated by a promoter of an ES cell-enriched gene into the cells. For the introduction of DNA into human ES cells, we have established a specific transfection protocol that is different from the one used for murine ES cells. Human ES cells were transfected with enhanced green fluorescence protein (EGFP), under the control of murine Rex1 promoter. The transfected cells show high levels of GFP expression when in an undifferentiated state. As the cells differentiate, this expression is dramatically reduced in monolayer cultures as well as in the primitive endoderm of early stage (simple) embryoid bodies (EBs) and in mature EBs. The undifferentiated cells expressing GFP can be analyzed and sorted by using a Fluorescence Activated Cell Sorter (FACS). Thus, we have established lines of human ES cells in which only undifferentiated cells are fluorescent, and these cells can be followed and selected for in culture. We also propose that the pluripotent nature of the culture is made evident by the ability of the homogeneous cell population to form EBs. The ability to efficiently transfect human ES cells will provide the means to study and manipulate these cells for the purpose of basic and applied research.


Cell Stem Cell | 2010

Differential modeling of Fragile X syndrome by human embryonic stem cells and induced-pluripotent stem cells

Achia Urbach; Ori Bar-Nur; George Q. Daley; Nissim Benvenisty

Document S1. Supplemental Experimental Procedures, Two Figures, and Two TablesxDownload (.34 MB ) Document S1. Supplemental Experimental Procedures, Two Figures, and Two Tables


Advances in Cancer Research | 2008

The Tumorigenicity of Human Embryonic Stem Cells

Barak Blum; Nissim Benvenisty

Human embryonic stem cells (HESCs) are the in vitro descendants of the pluripotent inner cell mass (ICM) of human blastocyst stage embryos. HESCs can be kept undifferentiated in culture or be differentiated to tissues representing all three germ layers, both in vivo and in vitro. These properties make HESC-based therapy remarkably appealing for the treatment of various disorders. Upon transplantation in vivo, undifferentiated HESCs rapidly generate the formation of large tumors called teratomas. These are benign masses of haphazardly differentiated tissues. Teratomas also appear spontaneously in humans and in mice. When they also encompass a core of malignant undifferentiated cells, these tumors are defined as teratocarcinomas. These malignant undifferentiated cells are termed embryonic carcinoma (EC), and are the malignant counterparts of embryonic stem cells. Here we review the history of experimental teratomas and teratocarcinomas, from spontaneous teratocarcinomas in mice to induced teratomas by HESC transplantation. We then discuss cellular and molecular aspects of the tumorigenicity of HESCs. We also describe the utilization of HESC-induced teratomas for the modeling of early human embryogenesis and for modeling developmental diseases. The problem of HESC-induced teratomas may also impede or prevent future HESC-based therapies. We thus conclude with a survey of approaches to evade HESC-induced tumor formation.

Collaboration


Dive into the Nissim Benvenisty's collaboration.

Top Co-Authors

Avatar

Ofra Yanuka

Hebrew University of Jerusalem

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lea Reshef

Hebrew University of Jerusalem

View shared research outputs
Top Co-Authors

Avatar

Tamar Golan-Lev

Hebrew University of Jerusalem

View shared research outputs
Top Co-Authors

Avatar

Yoav Mayshar

Hebrew University of Jerusalem

View shared research outputs
Top Co-Authors

Avatar

Ido Sagi

Hebrew University of Jerusalem

View shared research outputs
Top Co-Authors

Avatar

Joseph Itskovitz-Eldor

Hebrew University of Jerusalem

View shared research outputs
Top Co-Authors

Avatar

Neta Lavon

Hebrew University of Jerusalem

View shared research outputs
Top Co-Authors

Avatar

Amir Eden

Hebrew University of Jerusalem

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge